Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Stevanato Group SpA(STVN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for STVN
10/23/2026: STVN (1-star) is currently NOT-A-BUY. Pass it for now.
Stevanato Group is a specialized provider of pharmaceutical containment and drug delivery technology, serving global biopharma companies. Its core strength lies in an integrated model that combines high-precision glass manufacturing with proprietary automation machinery. The investment story centers on the secular trend toward injectable biologics, which require reliable, ready-to-use packaging solutions. Risks include high capital intensity, potential for supply chain disruptions, and competition from large, well-capitalized medical device peers. The stock may suit growth-oriented investors looking for exposure to the biopharma supply chain, though prospective investors should monitor capacity expansion milestones and raw material cost trends closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is a primary beneficiary of the long-term shift toward injectable biologics and complex drug delivery. |
| Momentum investor | Mixed fit | Performance is subject to cyclical pharma R&D cycles and plant expansion timelines. |
| Value investor | Mixed fit | Valuation often commands a premium due to high barriers to entry in the pharma supply chain. |
| Dividend investor | Weak fit | Capital is primarily prioritized for growth and facility reinvestment rather than high-yield payouts. |
| Low-risk investor | Mixed fit | The essential nature of pharma packaging provides stability, but capital expenditure risks remain. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | Market sentiment often fluctuates based on broader biopharma sector trends. |
| Valuation risk | Medium / high | The stock often trades at a premium due to growth expectations. |
| Competition risk (Pharma packaging) | Medium | Incumbent players maintain strong market positions. |
| Business quality | Strong | High-barrier, mission-critical product offerings create a strong franchise. |
| Dividend income | Low | Not structured as an income-generating investment. |
| Execution risk | Medium | Scaling global manufacturing capacity involves complex industrial risks. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -50.6% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.32B USD | Price to earnings Ratio 34.19 | 1Y Target Price 24.84 |
Price to earnings Ratio 34.19 | 1Y Target Price 24.84 | ||
Volume (30-day avg) 348.3K shares | Beta 0.78 | 52 Weeks Range 12.84 - 26.90 | Updated Date 10/24/2026 |
52 Weeks Range 12.84 - 26.90 | Updated Date 10/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.57 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Biopharmaceutical Solutions | Glass vials, syringes, cartridges, and complex drug delivery systems. | This is the core revenue driver, benefiting from the growing global demand for injectable drugs. |
| Engineering Systems | Vision inspection machines and automated assembly lines. | This segment provides technology that helps pharmaceutical companies optimize their own manufacturing. |
| Geography (Global) | Operations across Europe, North America, and Asia. | The company has a well-diversified global footprint that mitigates regional economic downturns. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 34.19 | Forward PE 28.65 | Enterprise Value 6.24B | Price to Sales(TTM) 4.34 |
Enterprise Value 6.24B | Price to Sales(TTM) 4.34 | ||
Enterprise Value to Revenue 4.39 | Enterprise Value to EBITDA 18.35 | Shares Outstanding 49.83M | Shares Floating 49.04M |
Shares Outstanding 49.83M | Shares Floating 49.04M | ||
Percent Insiders 1.78 | Percent Institutions 102.45 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.